Revolution Medicines (RVMD) Cash & Equivalents (2019 - 2026)

Revolution Medicines has reported Cash & Equivalents for 8 years, with the latest figure at $815.4 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 102.62% year-over-year to $815.4 million in Q2 2026; TTM through Jun 2026 was $815.4 million, a 102.62% increase from a year earlier, with the FY2025 full-year figure at $383.7 million, down 29.34% from the prior year.
• Cash & Equivalents was $815.4 million for Q2 2026 at Revolution Medicines, up from $440.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $815.4 million in Q2 2026, with the low at $97.7 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $350.4 million, with a median of $346.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 72.22% in 2022, then jumped 337.43% in 2023.
• Over 5 years, Cash & Equivalents stood at $161.4 million in 2022, then jumped by 331.29% to $696.1 million in 2023, then decreased by 21.99% to $543.1 million in 2024, then declined by 29.34% to $383.7 million in 2025, then jumped by 112.49% to $815.4 million in 2026.
• The last three Cash & Equivalents figures came in at $815.4 million (Q2 2026), $440.9 million (Q1 2026), and $383.7 million (Q4 2025), per Business Quant data.